Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: J Theor Biol. 2016 Jan 27;394:197–211. doi: 10.1016/j.jtbi.2016.01.026

Fig. 1.

Fig. 1.

Tumor escape when a standard anti-angiogenesis treatment is not continued, and is not combined with a treatment of unlicensed dendritic cells. Although tumor size is reduced significantly by a standard anti-VEGF treatment started on day 600, the tumor will eventually grow if the anti-VEGF treatment is not expanded, or if no follow-up DC immunotherapy is administered. (A) number of tumor cells, (B) concentration of free VEGF, (C) number of endothelial cells, and (D) total tumor vasculature.